Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Tepezza, Trodelvy, and More Drugs Now Available in Japan; Kisunla Due Out on Nov. 26
A throng of new medicines hit the Japanese market on November 20 upon their reimbursement listing, including Amgen’s Tepezza (teprotumumab) and Gilead Sciences’ Trodelvy (sacituzumab govitecan). Eli Lilly’s Alzheimer’s therapy Kisunla (donanemab) is set for release on November 26. Kisunla…
To read the full story
Related Article
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Pediatric Forms of Jakavi, More Drugs to Get Listing; Eylea Biosimilar Not on Roster
November 19, 2024
- Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
- Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
- Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
BUSINESS
- Takeda Returns to Core Profit Growth, CEO Confident in Trajectory
October 30, 2026
- Novartis Japan President Pullicino to Step Down for Global Role
October 30, 2026
- Lilly’s Imulrio Reaches Japan Market 10 Months after Approval
October 30, 2026
- Ono’s First-Half Operating Profit Up 11% Despite Forxiga Sales Hit
October 30, 2026
- Shionogi Logs Record H1 Revenue as Acquisitions Pay Off
October 30, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…